In the News
PPD lands praise from partner Moderna which reports strong results for COVID-19 vaccine
PPD’s 25 years of vaccine development experience essential to the successful execution of the study.
Training Isn’t a Drive-Thru
Amy Chapman explains that responding to a training request doesn’t need to be treated like a fast food order.
Advanced therapies: Navigation and application of EU and U.S. guidelines during product development
Kirsten Messmer and Richard Dennett provide a high-level overview and navigation guide through the multitude of available advanced therapy guidance in the EU and U.S.
Viral Vector API Characterization of Product-Related Impurities
A team of PPD® Laboratories scientists reviews existing analytical applications, focusing on viral vector characterization of impurities.
PPD’s roles in COVID-19 work continue with milestones
PPD is partnering with various pharma companies to develop treatments and vaccines for the coronavirus.
PPD expands in China with new multifunctional clinical research lab in Suzhou
The new operation will offer bioanalytical, biomarker and vaccine sciences services for global and China-based biopharma customers.
PPD opens new clinical research lab in China
New multipurpose laboratory will support China-based biotech companies and Western pharmaceutical companies managing China research studies.
Growing the pharma base
From a one-person consulting firm to a global contract research organization, PPD has been at the forefront of the clinical research industry in the Cape Fear region.
Two PPD Leaders Earn Life Sciences Industry Recognition
Those recognized are Karen Kaucic, chief medical officer of PPD and president of Evidera -- a PPD business -- and Rhonda Henry, vice president of patient centered trials at PPD.